In science, quality is everything. Whether you’re uncovering basic insights into the inner workings of biological systems or are on the front lines of developing the next generation of therapeutics or diagnostics, you want your results to stand the test of time. But reliable, reproducible data doesn’t just happen on its own. It takes smart experimental design, skilled execution, and tools you can trust to deliver data that’s both accurate and precise. And it also takes time.
At Ethos Biosciences, we want to give you back some of that time with assay kits, stains, reagents, and services that are high quality, easy to use, and quick to implement. From well thought-out kits designed to minimize preparatory steps and maximize accuracy, to expert support from the scientists that develop and manufacture each kit, to streamlined ordering, our goal is to simplify your path to the high-quality data that builds lasting and high-impact insights.
Ethos Biosciences was formed in 2018 as a subsidiary of Ott Scientific focused on the design, development, and manufacture of high-quality, easy-to-use assay kits, reagents, and services. In November 2018, we acquired the Exocell® diagnostics operation from Glycadia, Inc., as a first step in assembling a world-class product catalog.
With the Exocell acquisition, we not only incorporated the widely-cited products, many of which are considered the gold-standard assay in their respective areas, we’ve kept the entire operation. This means that current Exocell customers will continue to receive the same industry-leading products, services, and support that they’ve depended on since the company’s founding in 1988 by Margo Cohen, MD. Ph.D.
A leader in research on diabetes, endocrinology, and metabolism, Margo Cohen founded Exocell in 1988 to develop diabetes-related diagnostic products, and subsequently established Glycadia to develop therapeutic products. Under her leadership, Exocell® quickly became a leader in nephrology diagnostics with 15 patents and over 2000 research citations. Now a part of Ethos Biosciences, Exocell® products continue to serve the top academic, biotech, and pharma research teams across the globe.
Everyone talks about cancer and heart disease but not many people talk about kidney disease despite its status as the 9th leading cause of death in the United States. Over 700 million people worldwide have Chronic Kidney Disease which translates to over $120 billion in Medicare spending in the U.S. alone. One of the highest impact actions we collectively could make is to identify patients with CKD earlier in the disease cycle, especially because anyone with diabetes or hypertension (1/3 of the U.S. population) are at high risk for CKD. Disease progression can be slowed dramatically the earlier a patient understands their risks, begins medication, and/or changes their lifestyle. CKD is only a part of the picture, though. We also face healthcare challenges in Acute Kidney Injury, Polycystic Kidney Disease, Kidney Cancer, End Stage Renal Disease, and Kidney Transplants. Exocell focuses on advancing the worlds understanding of these different kidney diseases and helping to identify and diagnose them. Better diagnostics in the kidney space will lead to more research, better treatments, and better outcomes for renal disease patients.
Ott Scientific is a family owned and operated group of specialty chemical manufacturing companies with expertise in monomers, polymers, microspheres, and reagents for the pharmaceutical, medical device, and diagnostic industries.